Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Terminated
18 enrolled 18 charts
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Terminated
4 enrolled 10 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 2 Terminated
24 enrolled 10 charts
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
24 enrolled 13 charts
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Phase 2 Terminated
16 enrolled 19 charts
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Phase 2 Terminated
24 enrolled 15 charts
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Terminated
16 enrolled 7 charts
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Phase 2 Terminated
2 enrolled 13 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2 Terminated
31 enrolled 11 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
Phase 2 Terminated
2 enrolled 6 charts
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Phase 2 Terminated
6 enrolled 8 charts
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Phase 2 Terminated
7 enrolled 17 charts
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Terminated
2 enrolled 6 charts
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
Phase 2 Terminated
4 enrolled
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Terminated
5 enrolled 3 charts
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Phase 2 Terminated
14 enrolled 5 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
Phase 2 Terminated
51 enrolled
Cilengitide in Treating Patients With Acute Myeloid Leukemia
Phase 2 Terminated
70 enrolled
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Terminated
120 enrolled
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts